{"id":3330,"date":"2019-04-24T05:30:51","date_gmt":"2019-04-24T09:30:51","guid":{"rendered":"https:\/\/www.gensight-biologics.com\/gensight-biologics-publie-ses-resultats-financiers-2018\/"},"modified":"2026-09-24T00:09:41","modified_gmt":"2026-09-24T04:09:41","slug":"gensight-biologics-publie-ses-resultats-financiers-2018","status":"publish","type":"post","link":"https:\/\/www.gensight-biologics.com\/fr\/2019\/04\/24\/gensight-biologics-publie-ses-resultats-financiers-2018\/","title":{"rendered":"GenSight Biologics publie ses r\u00e9sultats financiers 2018"},"content":{"rendered":"\nParis, France, le 24 avril 2019, 7h30 CEST <\/strong>\u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, publie aujourd\u2019hui ses r\u00e9sultats financiers pour l\u2019exercice 2018. Les proc\u00e9dures d\u2019audit sur les comptes consolid\u00e9s ont \u00e9t\u00e9 effectu\u00e9es par les commissaires aux comptes. Le rapport de certification est en cours d\u2019\u00e9mission.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
En millions d\u2019euros<\/strong><\/td>\n2017<\/strong><\/td>\n2018<\/strong><\/td>\n<\/tr>\n
Produits op\u00e9rationnels<\/td>\n3,7<\/td>\n4,3<\/td>\n<\/tr>\n
D\u00e9penses de recherche et d\u00e9veloppement<\/td>\n(18,7)<\/td>\n(29,0)<\/td>\n<\/tr>\n
Frais g\u00e9n\u00e9raux<\/td>\n(8,2)<\/td>\n(7,0)<\/td>\n<\/tr>\n
Frais de vente et marketing<\/td>\n(0,8)<\/td>\n(1,4)<\/td>\n<\/tr>\n
R\u00e9sultat op\u00e9rationnel<\/td>\n(24,0)<\/td>\n(33,0)<\/td>\n<\/tr>\n
R\u00e9sultat net<\/td>\n(24,1)<\/td>\n(33,5)<\/td>\n<\/tr>\n
R\u00e9sultat par action (en euros par action)<\/td>\n(1,10)<\/td>\n(1,37)<\/td>\n<\/tr>\n
Flux de tr\u00e9sorerie net li\u00e9s aux activit\u00e9s op\u00e9rationnelles<\/td>\n(18,8)<\/td>\n(28,4)<\/td>\n<\/tr>\n
Flux de tr\u00e9sorerie net li\u00e9s aux activit\u00e9s d\u2019investissement<\/td>\n(0,7)<\/td>\n(0,7)<\/td>\n<\/tr>\n
Flux de tr\u00e9sorerie net li\u00e9s aux activit\u00e9s de financement<\/td>\n20,9<\/td>\n(0,1)<\/td>\n<\/tr>\n
(Diminution) \/ Augmentation de la tr\u00e9sorerie<\/strong><\/td>\n1,5<\/strong><\/td>\n(29,2)<\/strong><\/td>\n<\/tr>\n
Tr\u00e9sorerie et \u00e9quivalents de tr\u00e9sorerie \u00e0 la cl\u00f4ture<\/strong><\/td>\n55,4<\/strong><\/td>\n26,2<\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n \n\nLes produits op\u00e9rationnels<\/strong><\/span> de la Soci\u00e9t\u00e9 ont augment\u00e9 de 17,4% passant de 3,7 millions d\u2019euros en 2017 \u00e0 4,3 millions d\u2019euros en 2018. Ces produits ont \u00e9t\u00e9 principalement g\u00e9n\u00e9r\u00e9s par le Cr\u00e9dit Imp\u00f4t Recherche, qui s\u2019est \u00e9lev\u00e9 \u00e0 3,7 millions d\u2019euros et 4,3 millions d\u2019euros en 2017 et 2018, respectivement.\n\nLes d\u00e9penses de recherche et d\u00e9veloppement<\/strong><\/span> ont augment\u00e9 de 55,5% passant de 18,7 millions d\u2019euros en 2017 \u00e0 29,0 millions d\u2019euros en 2018. Cette variation significative refl\u00e8te l\u2019acc\u00e9l\u00e9ration continue des efforts de recherche et d\u00e9veloppement d’une part, \u00e0 la fois sur les activit\u00e9s de CMC et de production en anticipation d\u2019un d\u00e9p\u00f4t de dossier r\u00e9glementaire de GS010 attendu en Europe pour fin 2019, et de d\u00e9veloppement clinique avec trois \u00e9tudes de phase III en cours avec GS010 et une \u00e9tude de Phase I\/II avec GS030, ainsi qu\u2019un paiement d\u2019\u00e9tape dans le cadre d\u2019une licence pour GS030 relatif \u00e0 son entr\u00e9e en Phase I\/II en octobre 2018.\n\nLes frais g\u00e9n\u00e9raux<\/strong><\/span> ont baiss\u00e9 de 14,2% sur la p\u00e9riode, repr\u00e9sentant 8,2 millions d\u2019euros et 7,0 millions d\u2019euros en 2017 et 2018, respectivement. Cette baisse est principalement li\u00e9e aux d\u00e9penses de personnel, et plus sp\u00e9cifiquement \u00e0 la diminution des charges sociales et des d\u00e9penses non-cash g\u00e9n\u00e9r\u00e9es par les paiements en actions attribu\u00e9es au management et aux salari\u00e9s en 2016 et 2017.\n\n\u00a0<\/strong>Les frais de vente et marketing <\/strong><\/span>ont augment\u00e9 de 60,0% sur la p\u00e9riode, repr\u00e9sentant 0,8 million d\u2019euros et 1,4 millions d\u2019euros en 2017 et 2018, respectivement.\n\nLa perte nette <\/strong><\/span>de l\u2019exercice 2017 s\u2019\u00e9levait \u00e0 24,1 millions d\u2019euros contre une perte de 33,5 millions d\u2019euros au titre de 2018. La perte par action (nombre moyen pond\u00e9r\u00e9 d\u2019actions en circulation au cours de l\u2019exercice) s\u2019est \u00e9lev\u00e9e respectivement \u00e0 (1,10) et (1,37) euro par action pour les exercices 2017 et 2018, respectivement.\n\nLes flux de tr\u00e9sorerie nets li\u00e9s aux activit\u00e9s op\u00e9rationnelles<\/strong><\/span> en 2017 et 2018 se sont \u00e9lev\u00e9s respectivement \u00e0 (18,8) millions d\u2019euros et (28,4) millions d\u2019euros, sous l\u2019effet principalement d\u2019une augmentation significative des d\u00e9penses op\u00e9rationnelles partiellement compens\u00e9e par la baisse des charges non-cash relatives aux paiements en actions sur la p\u00e9riode.\n\nLes flux de tr\u00e9sorerie nets li\u00e9s aux activit\u00e9s de financement <\/strong><\/span>se sont \u00e9lev\u00e9s \u00e0 20,9 millions d\u2019euros en 2017 et (0,1) million d\u2019euros en 2018, refl\u00e9tant le produit net de l\u2019augmentation de capital r\u00e9alis\u00e9e dans le cadre du placement priv\u00e9 en juin 2017.\n\n \n\nGenSight Biologics publiera sa position nette de tr\u00e9sorerie, et ses r\u00e9sultats financiers semestriels au 30 juin 2019, le 24 juillet 2019.\n\n \n

\u00c0 propos de GenSight\u00a0Biologics<\/strong><\/h3>\nGenSight Biologics S.A. (GenSight Biologics) est une soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central. Le portefeuille de recherche de GenSight Biologics s\u2019appuie sur deux plates-formes technologiques : le ciblage mitochondrial (Mitochondrial Targeting Sequence<\/em>, ou MTS) et l\u2019optog\u00e9n\u00e9tique, visant \u00e0 pr\u00e9server ou restaurer la vision chez les patients atteints de maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine. Le candidat m\u00e9dicament le plus avanc\u00e9 de GenSight Biologics, GS010, est en Phase III pour le traitement de la neuropathie optique h\u00e9r\u00e9ditaire de Leber (NOHL), une maladie mitochondriale rare qui conduit \u00e0 une perte irr\u00e9versible de la vue chez les adolescents et les jeunes adultes. En utilisant son approche de th\u00e9rapie g\u00e9nique, les candidats m\u00e9dicaments de GenSight Biologics sont destin\u00e9s \u00e0 offrir aux patients une r\u00e9cup\u00e9ration visuelle fonctionnelle durable apr\u00e8s une seule injection intra-vitr\u00e9enne dans chaque \u0153il.\n","protected":false},"excerpt":{"rendered":"

Paris, France, le 24 avril 2019, 7h30 CEST \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, publie aujourd\u2019hui ses r\u00e9sultats financiers pour l\u2019exercice 2018. Les […]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[54],"tags":[],"featured-area":[],"news-topic":[79],"news-type":[76,80],"post-year":[],"class_list":["post-3330","post","type-post","status-publish","format-standard","hentry","category-communiques-de-presse-financiers","news-topic-company-and-personnel","news-type-corporate","news-type-finance"],"acf":[],"yoast_head":"\nGenSight Biologics publie ses r\u00e9sultats financiers 2018 - GenSight Biologics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.gensight-biologics.com\/fr\/2019\/04\/24\/gensight-biologics-publie-ses-resultats-financiers-2018\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenSight Biologics publie ses r\u00e9sultats financiers 2018 - GenSight Biologics\" \/>\n<meta property=\"og:description\" content=\"Paris, France, le 24 avril 2019, 7h30 CEST \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, publie aujourd\u2019hui ses r\u00e9sultats financiers pour l\u2019exercice 2018. Les […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.gensight-biologics.com\/fr\/2019\/04\/24\/gensight-biologics-publie-ses-resultats-financiers-2018\/\" \/>\n<meta property=\"og:site_name\" content=\"GenSight Biologics\" \/>\n<meta property=\"article:published_time\" content=\"2019-04-24T09:30:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-24T04:09:41+00:00\" \/>\n<meta name=\"author\" content=\"jbenedicto\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"jbenedicto\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2019\\\/04\\\/24\\\/gensight-biologics-publie-ses-resultats-financiers-2018\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2019\\\/04\\\/24\\\/gensight-biologics-publie-ses-resultats-financiers-2018\\\/\"},\"author\":{\"name\":\"jbenedicto\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\"},\"headline\":\"GenSight Biologics publie ses r\u00e9sultats financiers 2018\",\"datePublished\":\"2019-04-24T09:30:51+00:00\",\"dateModified\":\"2026-09-24T04:09:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2019\\\/04\\\/24\\\/gensight-biologics-publie-ses-resultats-financiers-2018\\\/\"},\"wordCount\":812,\"articleSection\":[\"Communiqu\u00e9 de presse Financier\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2019\\\/04\\\/24\\\/gensight-biologics-publie-ses-resultats-financiers-2018\\\/\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2019\\\/04\\\/24\\\/gensight-biologics-publie-ses-resultats-financiers-2018\\\/\",\"name\":\"GenSight Biologics publie ses r\u00e9sultats financiers 2018 - GenSight Biologics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\"},\"datePublished\":\"2019-04-24T09:30:51+00:00\",\"dateModified\":\"2026-09-24T04:09:41+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2019\\\/04\\\/24\\\/gensight-biologics-publie-ses-resultats-financiers-2018\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2019\\\/04\\\/24\\\/gensight-biologics-publie-ses-resultats-financiers-2018\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2019\\\/04\\\/24\\\/gensight-biologics-publie-ses-resultats-financiers-2018\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenSight Biologics publie ses r\u00e9sultats financiers 2018\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/\",\"name\":\"GenSight Biologics\",\"description\":\"Restoring vision while advancing gene therapy\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\",\"name\":\"jbenedicto\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"caption\":\"jbenedicto\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GenSight Biologics publie ses r\u00e9sultats financiers 2018 - GenSight Biologics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.gensight-biologics.com\/fr\/2019\/04\/24\/gensight-biologics-publie-ses-resultats-financiers-2018\/","og_locale":"fr_FR","og_type":"article","og_title":"GenSight Biologics publie ses r\u00e9sultats financiers 2018 - GenSight Biologics","og_description":"Paris, France, le 24 avril 2019, 7h30 CEST \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, publie aujourd\u2019hui ses r\u00e9sultats financiers pour l\u2019exercice 2018. Les […]","og_url":"https:\/\/www.gensight-biologics.com\/fr\/2019\/04\/24\/gensight-biologics-publie-ses-resultats-financiers-2018\/","og_site_name":"GenSight Biologics","article_published_time":"2019-04-24T09:30:51+00:00","article_modified_time":"2026-09-24T04:09:41+00:00","author":"jbenedicto","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"jbenedicto","Dur\u00e9e de lecture estim\u00e9e":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.gensight-biologics.com\/fr\/2019\/04\/24\/gensight-biologics-publie-ses-resultats-financiers-2018\/#article","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2019\/04\/24\/gensight-biologics-publie-ses-resultats-financiers-2018\/"},"author":{"name":"jbenedicto","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f"},"headline":"GenSight Biologics publie ses r\u00e9sultats financiers 2018","datePublished":"2019-04-24T09:30:51+00:00","dateModified":"2026-09-24T04:09:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2019\/04\/24\/gensight-biologics-publie-ses-resultats-financiers-2018\/"},"wordCount":812,"articleSection":["Communiqu\u00e9 de presse Financier"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.gensight-biologics.com\/fr\/2019\/04\/24\/gensight-biologics-publie-ses-resultats-financiers-2018\/","url":"https:\/\/www.gensight-biologics.com\/fr\/2019\/04\/24\/gensight-biologics-publie-ses-resultats-financiers-2018\/","name":"GenSight Biologics publie ses r\u00e9sultats financiers 2018 - GenSight Biologics","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#website"},"datePublished":"2019-04-24T09:30:51+00:00","dateModified":"2026-09-24T04:09:41+00:00","author":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f"},"breadcrumb":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2019\/04\/24\/gensight-biologics-publie-ses-resultats-financiers-2018\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.gensight-biologics.com\/fr\/2019\/04\/24\/gensight-biologics-publie-ses-resultats-financiers-2018\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.gensight-biologics.com\/fr\/2019\/04\/24\/gensight-biologics-publie-ses-resultats-financiers-2018\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.gensight-biologics.com\/fr\/home\/"},{"@type":"ListItem","position":2,"name":"GenSight Biologics publie ses r\u00e9sultats financiers 2018"}]},{"@type":"WebSite","@id":"https:\/\/www.gensight-biologics.com\/fr\/#website","url":"https:\/\/www.gensight-biologics.com\/fr\/","name":"GenSight Biologics","description":"Restoring vision while advancing gene therapy","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.gensight-biologics.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f","name":"jbenedicto","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","caption":"jbenedicto"}}]}},"_links":{"self":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3330","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/comments?post=3330"}],"version-history":[{"count":2,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3330\/revisions"}],"predecessor-version":[{"id":6510,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3330\/revisions\/6510"}],"wp:attachment":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/media?parent=3330"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/categories?post=3330"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/tags?post=3330"},{"taxonomy":"featured-area","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/featured-area?post=3330"},{"taxonomy":"news-topic","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-topic?post=3330"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-type?post=3330"},{"taxonomy":"post-year","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/post-year?post=3330"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}